{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:00:20Z","timestamp":1794344420011,"version":"4.9.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-1074-3","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T06:31:53Z","timestamp":1539930713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Yoshitaka","family":"Furuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Outi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Horiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuho","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent anti-tumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"1074_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","volume":"340","author":"K Okamoto","year":"2013","unstructured":"Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340:97\u2013103.","journal-title":"Cancer Lett"},{"key":"1074_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGER, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"1074_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330.","journal-title":"N Engl J Med"},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-3-319-91442-8_13","volume":"211","author":"S Zsch\u00e4bitz","year":"2018","unstructured":"Zsch\u00e4bitz S, Gr\u00fcllich C. Lenvantinib: a tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR\u03b1, KIT and RET. Recent Results Cancer Res. 2018;211:187\u201398. \n                    https:\/\/doi.org\/10.1007\/978-3-319-91442-8_13\n                    \n                  .","journal-title":"Recent Results Cancer Res"},{"key":"1074_CR6","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0002-9440(10)65515-0","volume":"155","author":"G Bunone","year":"1999","unstructured":"Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155:1967\u201376.","journal-title":"Am J Pathol"},{"key":"1074_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/ml500394m","volume":"6","author":"K Okamoto","year":"2014","unstructured":"Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2014;6:89\u201394.","journal-title":"ACS Med Chem Lett"},{"key":"1074_CR8","doi-asserted-by":"publisher","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2018 Aug 24. \n                    https:\/\/doi.org\/10.1111\/hepr.13243\n                    \n                   PMID: 30144256.","DOI":"10.1111\/hepr.13243"},{"key":"1074_CR9","unstructured":"Lenvima (Lenvatinib) prescribing information. Eisai Inc. Woodcliff Lake; 2015. Available at: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4665059\/\n                    \n                  . Accessed 7 Feb 2015."},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unsectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomized, double-blind, phase 3 trial. Lancet. 2014;384:319\u201328.","journal-title":"Lancet"},{"key":"1074_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2014;85:457\u201370.","journal-title":"Kidney Int"},{"issue":"Suppl","key":"1074_CR13","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.1200\/jco.2011.29.15_suppl.5503","volume":"29","author":"SI Sherman","year":"2011","unstructured":"Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011;29(Suppl):5503 abstract.","journal-title":"J Clin Oncol"},{"key":"1074_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","volume":"56","author":"RI Haddad","year":"2017","unstructured":"Haddad RI, Schlumberger M, Wirth LJ, et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017;56:121\u20138.","journal-title":"Endocrine"},{"key":"1074_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms18030625","volume":"18","author":"OV Ancker","year":"2017","unstructured":"Ancker OV, Wehland M, Bauer J, Infanger M, Grimm D. The adverse effect of hypertension in the treatment of thyroid cancer with multi-kinase inhibitors. Int J Mol Sci. 2017;18:625.","journal-title":"Int J Mol Sci"},{"key":"1074_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","volume":"23","author":"SM Bair","year":"2013","unstructured":"Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives-phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Trends Cardiovasc Med. 2013;23:104\u201313.","journal-title":"Trends Cardiovasc Med"},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/ijms17122073","volume":"17","author":"SW Aleksandra","year":"2016","unstructured":"Aleksandra SW, Arkadiusz L, Rafal S, Cezary S, Stanislaw N. Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients. Int J Mol Sci. 2016;17:2073.","journal-title":"Int J Mol Sci"},{"key":"1074_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s10147-014-0770-7","volume":"20","author":"H Miyake","year":"2015","unstructured":"Miyake H, Harada K, Imai S, Miyazaki A, Fujisawa M. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axinitib. Int J Clin Oncol. 2015;20:796\u2013801.","journal-title":"Int J Clin Oncol"},{"key":"1074_CR19","first-page":"460","volume":"29","author":"S Wu","year":"2011","unstructured":"Wu S, Jeresztes RS. Antiangiogenic agents for the treatment of non-small cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Investig. 2011;29:460\u201371.","journal-title":"Cancer Investig"},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","volume":"30","author":"M Ollero","year":"2015","unstructured":"Ollero M, Sahali D. Inhibition of the VEGF signaling pathway and glomerular disorders. Nephrol Dial Transplant. 2015;30:1449\u201355.","journal-title":"Nephrol Dial Transplant"},{"key":"1074_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129\u201336.","journal-title":"N Engl J Med"},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal disease. J Clin Invest. 2003;111:707\u201316.","journal-title":"J Clin Invest"},{"key":"1074_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BYY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:560\u201376.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","volume":"69","author":"A Hara","year":"2006","unstructured":"Hara A, Wada T, Furuuchi K, et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 2006;69:1986\u201395.","journal-title":"Kidney Int"},{"key":"1074_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.147","volume":"114","author":"MJ Sorich","year":"2016","unstructured":"Sorich MJ, Rowland A, Kichenadasse G, Woodman RJ, Mangoni AA. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer. 2016;114:1313\u20137.","journal-title":"Br J Cancer"},{"key":"1074_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/annonc\/mdp472","volume":"21","author":"EN Overkleeft","year":"2010","unstructured":"Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010;21:184\u20135.","journal-title":"Ann Oncol"},{"key":"1074_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ndt\/gfp666","volume":"25","author":"O Costero","year":"2010","unstructured":"Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010;25:1001\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"1074_CR28","doi-asserted-by":"publisher","first-page":"F614","DOI":"10.1152\/ajprenal.00616.2014","volume":"308","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Ueno T, Ohashi K, Ohashi K, Michio N. Podocyte injury-driven intracapillary PAI-1 accelerates podocyte loss via beta 1 integrin endocytosis. Am J Physiol Renal Physiol. 2015;308:F614\u201326.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1074_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1681\/ASN.2010030295","volume":"21","author":"K Sison","year":"2010","unstructured":"Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010;21:1691\u2013701.","journal-title":"J Am Soc Nephrol"},{"key":"1074_CR30","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1681\/ASN.2010040378","volume":"21","author":"J Peti-Peterdi","year":"2010","unstructured":"Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010;21:1835\u201341.","journal-title":"J Am Soc Nephrol"},{"key":"1074_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000168082","volume":"10","author":"H Shiiki","year":"1990","unstructured":"Shiiki H, Dohi K, Hanatani M, et al. Focal segmental glomerulosclerosis in preeclamptic patients with nephrotic syndrome. Am J Nephrol. 1990;10:205\u201312.","journal-title":"Am J Nephrol"},{"key":"1074_CR32","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ki.2008.256","volume":"74","author":"MB Stokes","year":"2008","unstructured":"Stokes MB, Erazo MC, Agati DD. Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008;74:1487\u201391.","journal-title":"Kidney Int"},{"key":"1074_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s10157-011-0543-9","volume":"16","author":"D Takahashi","year":"2012","unstructured":"Takahashi D, Nagahama K, Tsuura Y, Tanaka H, Tamura T. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction. Clin Exp Nephrol. 2012;16:310\u20135.","journal-title":"Clin Exp Nephrol"},{"key":"1074_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","volume":"8","author":"C Frangie","year":"2007","unstructured":"Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF antibody treatment for metastatic renal cell carcinoma. Lancet Oncol. 2007;8:177\u20138.","journal-title":"Lancet Oncol"},{"key":"1074_CR35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfn657","volume":"24","author":"G Bollee","year":"2009","unstructured":"Bollee G, Patey N, Cazajous G, Knebelmann B. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1074_CR36","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/ndt\/gfr093","volume":"26","author":"K Stylianou","year":"2011","unstructured":"Stylianou K, Lioudaki E, Papadimitraki E, et al. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Nephrol Dial Transplant. 2011;26:1742\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1074_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000241551","volume":"2","author":"YS Chen","year":"2009","unstructured":"Chen YS, Chen CL, Wang JS. Nephrotic syndrome and acute renal failure apparently induced by sunitinib. Case Rep Oncol. 2009;2:172\u20136.","journal-title":"Case Rep Oncol"},{"key":"1074_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ndt\/gfn625","volume":"24","author":"S Winn","year":"2009","unstructured":"Winn S, Ellis S, Savage P, Sampson S, Marsh JE. Biopsy proven acute intestinal nephritis associated with tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant. 2009;24:673\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1074_CR39","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","volume":"45","author":"J Usui","year":"2014","unstructured":"Usui J, Glezerman IG, Salvatore SP, Chandranb CB, Flonbaum CD, Seshan SV. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Hum Pathol. 2014;45:1918\u201327.","journal-title":"Hum Pathol"},{"key":"1074_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"DH Johnson","year":"2005","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2005;23:792\u20139.","journal-title":"J Clin Oncol"},{"key":"1074_CR41","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom K, Fehrenbacher L. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792\u20139.","journal-title":"J Clin Oncol"},{"key":"1074_CR42","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","volume":"49","author":"BA George","year":"2007","unstructured":"George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007;49:e23\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1074_CR43","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/ndt\/gfp140","volume":"24","author":"EJ Rolleman","year":"2009","unstructured":"Rolleman EJ, Weening J, Betjes MG. Acute nephrotic syndrome after anti-VEGF therapy for renal cell carcinoma. Nephrol Dial Transplant. 2009;24:2002\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"1074_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF). An 8-year observational study at a single center. Medicine. 2014;93:333\u20139.","journal-title":"Medicine"},{"key":"1074_CR45","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuroscience.2009.05.019","volume":"162","author":"V Echeverria","year":"2009","unstructured":"Echeverria V, Burgess S, Gamble-George J, et al. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience. 2009;162:1220\u201331.","journal-title":"Neuroscience"},{"key":"1074_CR46","first-page":"ra39","volume":"3","author":"SY Zhang","year":"2010","unstructured":"Zhang SY, Kamal M, Dahan K, et al. c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal. 2010;3:ra39.","journal-title":"Sci Signal"},{"key":"1074_CR47","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ajpath.2012.02.008","volume":"180","author":"V Ory","year":"2012","unstructured":"Ory V, Fan O, Hamadaoui N, et al. c-mip down-regulates NF-\u03baB activity and promotes apoptosis in podocytes. Am J Pathol. 2012;180:2284\u201392.","journal-title":"Am J Pathol"},{"key":"1074_CR48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cellsig.2012.11.017","volume":"25","author":"L Yu","year":"2013","unstructured":"Yu L, Lin Q, Feng J, et al. Inhibition of nephilim activation by c-mip through Csk-Cbp-Fyn axis plays a critical role in angiotensin II-induced podocyte damage. Cell Signal. 2013;25:581\u20138.","journal-title":"Cell Signal"},{"key":"1074_CR49","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signaling inhibition-induced proteinuria: mechanism, significance and management. Eur J Cancer. 2010;46:439\u201348.","journal-title":"Eur J Cancer"},{"key":"1074_CR50","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1074_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1078155214563153","volume":"22","author":"JD Land","year":"2016","unstructured":"Land JD, Chen AH, Atkinson BJ. Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract. 2016;22:235\u201341.","journal-title":"J Oncol Pharm Pract"},{"key":"1074_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3904\/kjim.2014.29.1.40","volume":"29","author":"SH Baek","year":"2014","unstructured":"Baek SH, Kim H, Lee J, et al. Renal adverse effects of sunitinib and its clinical significance: A single-center experience in Korea. Korean J Intern Med. 2014;29:40\u20138.","journal-title":"Korean J Intern Med"},{"key":"1074_CR53","unstructured":"Japanese Society of Nephrology, Japan Society of Clinical Oncology, Japanese Society of Medical Oncology, and the Japanese Society of Nephrology and pharmacotherapy. Clinical practice guidelines for the management of kidney disease in cancer survivors. 2016."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1074-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T19:18:41Z","timestamp":1571426321000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1074-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1074-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient received an explanation of the procedures and possible risk of this study. The patient provided written informed consent according to the policy of the Ethical Review Board in the NTT Medical Centre Tokyo.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"273"}}